Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARA: LDASA in SARS-CoV-2 Infected Pregnant Women
NCT05073718Phase 3Completed
- Sponsor
- Barcelona Institute for Global Health
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aspirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Barcelona Institute for Global Health. Primary endpoint: Rate of composite adverse maternal and perinatal adverse outcomes up to 37 weeks. Started Sep 2022; status: completed.
02
Drugs
aspirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05073718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073718.